BioXcel Therapeutics (BTAI) Long-Term Debt Repayments (2026)
BioXcel Therapeutics' (BTAI) quarterly Long-Term Debt Repayments came in at $2.5 million in Q1 2026.
BioXcel Therapeutics (BTAI) Long-Term Debt Repayments (2026) Analysis & Trends
BioXcel Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a N/A change from a year earlier, with the FY2024 full-year figure at $2.5 million, changed N/A from the prior year.
- Long-Term Debt Repayments held at $2.5 million in Q1 2026 per BTAI's latest filing.
- Across five years, Long-Term Debt Repayments topped out at $2.5 million in Q1 2026 and bottomed at $2.5 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 23.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -478.39 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 | 2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.50 Mn |
| Mar 31, 2026 | 2.50 Mn |